Skip to main content
. 2016 Mar 7;7(15):20455–20468. doi: 10.18632/oncotarget.7973

Figure 6.

Figure 6

(A) The effects of repeated pre-administration of 5-HT1A antagonist WAY-100635 (1 mg/kg) on thermal hyeralgesia in sham and CCI mice. (B) The effects of repeated pre-administration of 5-HT1B antagonist isamoltane (2.5 mg/kg) on thermal hyeralgesia in sham and CCI mice. (C) The effects of repeated pre-administration of 5-HT2A/2C antagonist ritanserin (4 mg/kg) on thermal hyeralgesia in sham and CCI mice. (D) The effects of repeated pre-administration of t 5-HT3 antagonist ondansetron (0.5 mg/kg) on thermal hyeralgesia in sham and CCI mice. (E) Effect of pre-administration of different dose 5-HT1A antagonist on thermal hyeralgesia in FA-treated CCI mice. (F) Intrathecal (i.t.), but not itracerebroventricular (i.c.v.) injection of 5-HT1A antagonist WAY-100635 (0.15 μg/μl for i.t. injection; 2 μg/μl for i.c.v. injection) abolished the analgesic action of FA on thermal hyeralgesia in CCI mice. Results are expressed as mean ± SEM from 8 mice. *p < 0.05 vs. vehicle-treated sham group; #p < 0.05 vs. vehicle-treated CCI group.